Aziyo Biologics Presents Clinical Data On CanGaroo Biologic Envelope In Patients Receiving Cardiac Implantable Electronic Devices
Portfolio Pulse from Vandana Singh
Aziyo Biologics Inc (NASDAQ:AZYO) announced that data from the HEAL Study will be presented at the Heart Rhythm Society, comparing the performance of its CanGaroo Envelope with Medtronic Plc's (NYSE:MDT) Tyrx non-biologic envelope and no envelope in patients receiving cardiac implantable electronic devices. The CanGaroo Envelope showed better results in several aspects, and AZYO shares are up 4.72% at $2.22.
May 19, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aziyo Biologics' CanGaroo Envelope showed better results in the HEAL Study, and its shares are up 4.72% at $2.22.
The HEAL Study data presentation at the Heart Rhythm Society shows that Aziyo Biologics' CanGaroo Envelope performed better than Medtronic's Tyrx non-biologic envelope and no envelope in several aspects. This positive news is likely to boost investor confidence in the company and its product, leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Aziyo Biologics' CanGaroo Envelope outperformed Medtronic's Tyrx non-biologic envelope in the HEAL Study.
The HEAL Study data presentation shows that Aziyo Biologics' CanGaroo Envelope performed better than Medtronic's Tyrx non-biologic envelope in several aspects. This may lead to increased competition for Medtronic in the cardiac implantable electronic devices market and could have a short-term negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 80